在利特昔替尼与布雷波替尼2a期随机试验中表征斑秃患者报告结局与临床医生评估之间的关系
2a期ALLEGRO试验纳入成人斑秃患者,随机接受利特昔替尼(n=48)、布雷波替尼(n=47)或安慰剂(n=47)。第24周时,两个活性治疗组的AASIS评分较安慰剂显著改善,SALT评分较基线改善,AASIS与SALT评分呈中度至高度相关。
要点
- 第24周时,利特昔替尼组AASIS评分较安慰剂的最小二乘均数差为-0.8至-2.3,布雷波替尼组为-0.9至-3.7,均P<0.05。
- 第24周时,利特昔替尼组平均SALT评分(标准差)为54.4(40.3),基线为89.4(15.8);布雷波替尼组为31.9(35.7),基线为86.4(18.1)。
- 第24周时,AASIS整体及子量表评分与SALT评分的相关系数为0.34至0.58,均P<0.05。
核心结论
- 随机接受利特昔替尼或布雷波替尼的患者在第24周报告AASIS和SALT评分较安慰剂显著改善。
- 第24周时,AASIS整体及子量表评分与SALT评分呈中度至高度相关。
- 作者使用AASIS工具的体验提示需要新的患者报告结局工具来准确评估斑秃相关体征、症状和日常功能。
研究设计与样本
- 2a期ALLEGRO随机对照试验(NCT02974868),纳入成人斑秃患者,随机分为利特昔替尼组(n=48)、布雷波替尼组(n=47)和安慰剂组(n=47)。
- 第24周后,采用重复测量混合效应模型计算活性治疗组AASIS评分的最小二乘均数差。
- 采用合并数据,通过Pearson相关系数评估基线和第24周时AASIS与SALT评分的关系。
主要发现
- 基线时各治疗组AASIS和SALT评分相似。
- 第24周时,两个活性治疗组AASIS评分均显著改善:利特昔替尼组较安慰剂的最小二乘均数差为-0.8至-2.3,布雷波替尼组为-0.9至-3.7,均P<0.05。
- 第24周时,利特昔替尼组平均SALT评分(标准差)为54.4(40.3),基线为89.4(15.8);布雷波替尼组为31.9(35.7),基线为86.4(18.1)。
- 第24周时,AASIS整体及子量表评分与SALT评分的相关系数为0.34至0.58,均P<0.05。
关键数值与推荐
- 第24周时,利特昔替尼组AASIS评分较安慰剂的最小二乘均数差为-0.8至-2.3(P<0.05)。
- 第24周时,布雷波替尼组AASIS评分较安慰剂的最小二乘均数差为-0.9至-3.7(P<0.05)。
- 第24周时,AASIS整体及子量表评分与SALT评分的相关系数为0.34至0.58(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF-06651600) and brepocitinib (PF-06700841) in adults with alopecia areata. No randomized controlled trial for alopecia areata has evaluated correlations between clinician-assessed hair loss and patient-reported outcomes. OBJECTIVES: Report scores from the Alopecia Areata Symptom Impact Scale (AASIS; a patient-reported outcome tool) and explore the relationships of those scores with clinician-assessed Severity of Alopecia Tool (SALT) scores at baseline and week 24 of the ALLEGRO trial. METHODS: Adults with alopecia areata were randomized to ritlecitinib (n = 48), brepocitinib (n = 47) or placebo (n = 47). After 24 weeks, the mixed-effects model with repeated measures was used to calculate the active treatment groups' AASIS score least-squares mean differences. Relationships between AASIS and SALT scores at baseline and week 24 were evaluated by Pearson's correlation coefficients using pooled data. RESULTS: Baseline AASIS and SALT scores were similar among treatment groups. Both active treatment groups reported significant improvements in AASIS scores at week 24 (least-squares mean differences vs. placebo for ritlecitinib, -0.8 to -2.3; brepocitinib, -0.9 to -3.7; P < 0.05 for all). At week 24, the mean SALT scores (standard deviation) improved compared with baseline [ritlecitinib, 54.4 (40.3) vs. 89.4 (15.8); brepocitinib, 31.9 (35.7) vs. 86.4 (18.1)]. The correlation coefficients between AASIS global and subscale scores and SALT scores at week 24 ranged from 0.34 to 0.58; P < 0.05 for all. CONCLUSIONS: Patients randomized to ritlecitinib or brepocitinib reported significantly improved AASIS and SALT scores at week 24 of the ALLEGRO trial compared to placebo. At week 24, medium-to-large correlations can be seen between AASIS global and subscale scores and SALT scores. Our experience with AASIS instrument highlighted several aspects that suggest new patient-reported outcome tools are needed to accurately assess patients' relevant alopecia areata related signs, symptoms and daily functioning.
引用
- Winnette R, Banerjee A, Sikirica V, et al. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J Eur Acad Dermatol Venereol. 2022. PMID: 35000236. doi:10.1111/jdv.17909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。